Clinical trials: Lou Gehrig's Disease

Amyotrophic Lateral Sclerosis

Phase 3 Study of Dexpramipexole in ALS

• Completed
• Age: 18 to 80 years
• Phase 3
• Results posted

The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).

Trial name

EMPOWER (NCT01281189)

Testing

Dexpramipexole

Where

82 sites in United States, Australia and 9 more

Volunteers

942 people

Sponsor

Knopp Biosciences